We are live on ! Find out more

Immuron

IMRN

Market cap $6.88M

0.8529 USD

-0.0072

0.84%

At close Updated Nov 4, 4:00 PM EST

1 day

-0.84%

5 days

-5.24%

1 month

-20.29%

3 months

-21.03%

6 months

5.85%

Year to date

7.28%

1 year

-50.7%

5 years

-77.61%

10 years

-89.8%

About: Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.

Employees: 8

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 20%

Neutral 80%

Negative 0%

Immuron continued quarterly sales growth

Sales Highlights (unaudited): Global Q1 sales AUD$2.2 million up 9% on prior comparative period (pcp) Q1 sales up 5% on prior quarter Australia Q1 sales AUD$1.8 million up 14% on prior comparative period (pcp) Q1 sales up 12% on prior quarter Canada Q1 sales AUD$0.1 million up 286% on prior comparative period (pcp) Q1 sales up 63% on prior quarter USA Q1 sales AUD$0.3 million down 19% on prior comparative period (pcp) Q1 sales down 24% on prior quarter MELBOURNE, Australia, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce double digit sales growth (unaudited) in the quarter ending September 30, 2026. Continued Travelan® Australian sales growth in Q1 FY27 (+14% on pcp) in Australia can be attributed to the new Travelan® brand re-launch, including new packaging and associated brand communications which has resonated strongly with consumers and has been well received and supported by all the major pharmacy banner groups.

Immuron continued quarterly sales growth

Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference

MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Emerging Growth Conference on Wednesday 28th October 2026 (4:25pm – 4:55pm U.S. Eastern Time).

Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference

Travelan® Phase 2 Study Results Published

MELBOURNE, Australia, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that data from its Phase 2 clinical trial of once-daily oral Travelan® has been published in the Nature Journal, Scientific Reports. A copy of the publication can be accessed here: https://doi.org/10.1038/s41598-026-70974-9 The article titled, "A phase 2, randomized, placebo-controlled study to evaluate once-daily oral Travelan for the prevention of Travellers' Diarrhoea," describes clinical data previously announced to the ASX on March 7, 2024.

Travelan® Phase 2 Study Results Published

Immuron Stock Surges Friday: What's Driving the Action?

Shares of Immuron Limited (NASDAQ:IMRN) are surging Friday morning following news that the Australian biopharmaceutical company signed an exclusive agreement to launch PROIBS gut health product in the United States. Here's what investors need to know.

Immuron Stock Surges Friday: What's Driving the Action?

Immuron to launch PROIBS® in the United States

MELBOURNE, Australia, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has executed an exclusive distribution agreement for PROIBS® in the United States with Calmino group AB. Immuron launched PROIBS® in Australia during FY26.

Immuron to launch PROIBS® in the United States

Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year

MELBOURNE, Australia, July 16, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.

Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year

Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy

Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy Immuron is seeking a partner to support clinical development through regulatory approval and commercialization Immuron has U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application IND 32095 is Immuron's Investigational new drug (IND) application for clinical development of IMM-529 as a product to specifically prevent or treat Clostridioides difficile infection (CDI) MELBOURNE, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has engaged Pullan Consulting to provide business development services to assist in securing a strategic partnership for IMM-529. Pullan Consulting is a highly regarded life sciences advisory firm with a strong track record of executing between five and twelve partnering transactions annually over the past 20 years.

Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy

Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00

NEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today released a Flash Report on Immuron (Nasdaq:IMRN), maintaining its Buy-Extended rating while increasing its 12-month price target to $4.00 (from $3.90), representing significant upside from the current share price of $0.9268 as of April 21, 2026. The Flash Report highlights Immuron's continued revenue growth, expanding commercial footprint, and progress within its clinical development pipeline.

Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00

Immuron Double Digit 3Q Sales Growth

Sales Highlights (unaudited): Global Q3 sales AUD$1.5 million up 16% on prior comparative period (pcp) YTD Mar 2026 sales AUD$5.7 million up 7% on prior comparative period (pcp) Australia Q3 sales AUD$0.9 million up 15% on prior comparative period (pcp) YTD Mar 2026 sales AUD$4.2 million up 14% on prior comparative period (pcp) Canada Q3 sales AUD$0.1 million up >100% on prior comparative period (pcp) Q3 sales up 82% on prior quarter; initial sales to Jean Coutu, Quebec YTD Mar 2026 sales AUD$0.1 million down 65% on prior comparative period (pcp) USA Q3 sales AUD$0.5 million up 1% on prior comparative period (pcp) YTD Mar 2026 sales AUD$1.3 million up 10% on prior comparative period (pcp) MELBOURNE, Australia, April 17, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. Continued Travelan® Q3 sales growth ( +15% on pcp) in Australia can be contributed to: (1) increased awareness and consideration driven by extensive digital and social media marketing.

Immuron Double Digit 3Q Sales Growth

Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target

NEW YORK CITY, NEW YORK / ACCESS Newswire / March 5, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited (Nasdaq:IMRN), maintaining its Buy-Extended rating and 12-month price target of $3.90 following the Company's release of first-half fiscal year 2026 financial results and strategic update. The Flash Report notes that Immuron reported global product revenue of AUD $4.18 million for the six months ended December 31, 2025, representing approximately 5% growth compared to the prior-year period.

Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target

See News Rankings

Price charts implemented using Lightweight Charts™